STERIS plc Form 4 Filings

Shapiro Louis reported acquisition or exercise transactions in this Form 4 filing.

STERIS plc director Louis Shapiro received a grant of 1,025 Career Restricted Stock Units, each representing one ordinary share. These units are fully vested immediately and will be settled in ordinary shares six months after the cessation of his Board service, bringing his reported derivative holdings to 2,000 units.

STERIS plc director Nirav R. Shah reported equity awards consisting of stock options and restricted stock units. On 2026-08-10, he received 1,506 nonqualified stock options to purchase STERIS ordinary shares at an exercise price of $238.91 per share; these options are fully vested and exercisable immediately, and expire on 2036-08-10. On the same date, he also received 512 Career Restricted Stock Units, each representing one ordinary share to be delivered six months after his Board service ends; these RSUs are fully vested immediately. Following the RSU grant, his directly held equity related to these units totals 7,015 shares.

Martin Paul Edward reported acquisition or exercise transactions in this Form 4 filing.

STERIS plc director Martin Paul Edward reported compensation-related equity grants. He received 1,506 nonqualified stock options exercisable immediately at $238.91 per share, expiring August 10, 2036, and 512 Career Restricted Stock Units, which are fully vested and will be settled in ordinary shares six months after his Board service ends, bringing his directly held Career RSUs to 5,074.

HOLLAND CHRISTOPHER S reported acquisition or exercise transactions in this Form 4 filing.

STERIS plc director Christopher S. Holland received a grant of 1,025 Career Restricted Stock Units, each representing the right to receive one ordinary share. The units are fully vested immediately and will be settled in ordinary shares six months after his Board service ends. Following this award, he directly holds 5,989 Career Restricted Stock Units.

STERIS plc director Cynthia L. Feldmann received equity awards on 2026-08-10. She was granted 1,506 nonqualified stock options to buy ordinary shares at an exercise price of $238.91 per share, fully vested and exercisable immediately, expiring on 2036-08-10. She also received 512 fully vested Career Restricted Stock Units, each representing one ordinary share to be settled six months after her Board service ends, bringing her directly held Career RSUs to 8,640 units.

Boulud Pierre reported acquisition or exercise transactions in this Form 4 filing.

STERIS plc reported that director Pierre Boulud received a grant of 1,025 Career Restricted Stock Units, each representing the right to receive one STERIS ordinary share. The units are fully vested immediately and will be settled in ordinary shares six months after the cessation of the Director's Board service, bringing his reported direct holdings in these units to 1,392.

STERIS plc director Esther M. Alegria received new equity-based compensation. On 2026-08-10 she was granted 1,506 nonqualified stock options with an exercise price of $238.91 per share, expiring on 2036-08-10; these options are fully vested and exercisable immediately. She was also granted 512 Career Restricted Stock Units, each representing one ordinary share, which are fully vested and will be settled in shares six months after her Board service ends. Following these awards, her directly held derivative interests reported in this filing total 3,408 Career RSUs and 1,506 stock options.

STERIS plc director Mohsen Sohi exercised a fully vested option to purchase 3,781 ordinary shares at $71.40 per share, an award originally received in connection with the company’s 2019 redomiciliation. In a net cashless exercise, options relating to 1,837 shares were surrendered to pay the option price. After these transactions, he directly owned 24,305 ordinary shares. The filing indicates the transactions were not made under a Rule 10b5-1 trading plan.

STERIS plc senior vice president, general counsel and secretary John Adam Zangerle reported an open-market sale of 1,419 Ordinary Shares at $209.28 per share. After this transaction, he directly holds 35,259 Ordinary Shares.

As of June 15, 2026, 8,239 of these Ordinary Shares are restricted, with restrictions scheduled to lapse in stages between June 2, 2027 and June 4, 2029.

STERIS plc senior executive reports routine tax withholding transaction. On June 4, 2026, Sr. VP and General Counsel John Adam Zangerle had 401 ordinary shares withheld at $212.24 per share to cover taxes on 1,376 restricted shares that vested that day, rather than selling shares in the market.

After this withholding, he directly holds 36,678 ordinary shares, including 8,239 restricted shares as of June 8, 2026. The remaining restricted shares are scheduled to lapse in stages through June 4, 2029, reflecting ongoing equity-based compensation.

STERIS plc reported that V.P. & Corporate Treasurer Renato Tamaro had 65 Ordinary Shares withheld on June 4, 2026 as a tax-withholding disposition tied to a restricted share vesting. The 65 shares came from 221 restricted shares that vested that day and were valued at the NYSE closing price on June 4, 2026. Following this withholding, Tamaro directly holds 6,194 Ordinary Shares, of which 1,405 remain restricted. These restrictions are scheduled to lapse in tranches between June 2, 2027 and June 4, 2029.

STERIS plc senior vice president Julia Madsen reported a routine tax-withholding transaction tied to vesting equity awards. On June 4, 2026, 195 ordinary shares were disposed of at $212.24 per share to cover taxes due on 542 restricted shares that vested that day.

After this withholding, Madsen directly holds 12,257 ordinary shares of STERIS, including 4,190 restricted shares as of June 8, 2026. These restricted shares are scheduled to lapse in tranches between June 2, 2027 and June 4, 2029.

STERIS plc SVP & GM, AST Kenneth E. Kohler reported a routine tax-related share disposition. On June 4, 2026, 150 ordinary shares were withheld from 513 restricted shares that vested, to cover taxes based on the NYSE closing price of $212.24 per share. After this, he directly holds 11,332 ordinary shares, including 3,972 restricted shares scheduled to lapse between 2027 and 2029.

STERIS plc senior executive Mary Clare Fraser reported a routine tax-withholding transaction related to restricted share vesting. On June 4, 2026, 600 ordinary shares were withheld at $212.24 per share to cover taxes on 1,360 restricted shares that vested that day. After this tax-withholding disposition, she directly owns 13,716 ordinary shares, including 5,359 restricted shares. The restricted shares are scheduled to lapse in stages between June 2027 and June 2029, reflecting ongoing equity-based compensation rather than an open-market sale.

STERIS plc President and CEO Daniel A. Carestio reported a net sale of 4,428 Ordinary Shares in open‑market transactions. He sold 3,054 shares at $214.64 on June 4, 2026 and 1,374 shares at $212.00 on June 5, 2026.

On June 4, 2026, 1,889 shares were withheld to cover taxes on 4,283 restricted shares that vested, a non‑market tax-withholding disposition. After these transactions, he directly owns 63,647 Ordinary Shares. As of June 8, 2026, 39,893 of these shares remain restricted and are scheduled to vest in tranches through June 4, 2029.

STERIS plc Senior Vice President and CFO Karen L. Burton reported a routine tax-withholding transaction. On June 4, 2026, 90 ordinary shares were withheld at $212.24 per share from 306 restricted shares that vested to cover required taxes, not an open-market sale.

After this transaction, Burton directly holds 13,184 ordinary shares, including 9,282 restricted shares as of June 8, 2026, which are scheduled to lapse in stages between October 1, 2026 and June 4, 2029.

STERIS plc senior vice president and general counsel John Adam Zangerle reported a routine tax-withholding transaction related to vested stock. On June 3, 2026, 365 ordinary shares were withheld from 1,252 restricted shares that vested, using the NYSE closing price of $210.19 per share to cover required taxes. After this withholding, he directly holds 37,079 ordinary shares. As of June 3, 2026, 9,615 of these shares remain restricted, with restrictions scheduled to lapse in several tranches between June 4, 2026 and June 4, 2029.

STERIS plc executive Renato Tamaro reported a routine tax-related share withholding tied to restricted stock vesting. On June 3, 2026, 64 ordinary shares valued at $210.19 per share were withheld to cover taxes from 217 restricted shares that vested that day. After this transaction, Tamaro directly owned 6,259 ordinary shares, of which 1,626 remained restricted and will vest in scheduled tranches between June 2026 and June 2029. This event reflects compensation and tax mechanics rather than an open-market sale.

STERIS plc senior executive Julia Madsen reported a routine tax-withholding transaction linked to restricted share vesting. On June 3, 2026, 239 ordinary shares valued at $210.19 per share were withheld from 666 restricted shares that vested, to cover taxes determined under applicable laws using the NYSE closing price.

After this withholding, Madsen directly held 12,452 ordinary shares, including 4,732 restricted shares as of June 3, 2026. These restricted shares are scheduled to lapse in stages between June 4, 2026 and June 4, 2029.

STERIS plc senior executive Kenneth E. Kohler reported a routine tax-withholding transaction related to restricted stock vesting. On June 3, 2026, 184 ordinary shares were withheld at a value of $210.19 per share to cover taxes on 630 restricted shares that vested that day.

After this tax-withholding disposition, Kohler directly holds 11,482 ordinary shares of STERIS, of which 4,485 remain restricted as of June 3, 2026. These restricted shares are scheduled to lapse in stages between June 4, 2026 and June 4, 2029, reflecting ongoing equity-based compensation rather than open-market trading.

STERIS plc senior executive handles tax withholding on vested shares. SVP & Chief HRO Mary Clare Fraser had 311 ordinary shares withheld on June 3, 2026 to cover taxes on 835 restricted shares that vested, based on the NYSE closing price that day. After this non-market tax-withholding disposition, she directly holds 14,316 ordinary shares, including 6,719 restricted shares scheduled to lapse in stages between June 4, 2026 and June 4, 2029.

STERIS plc President and CEO Daniel A. Carestio reported a routine tax-withholding transaction related to vesting restricted stock. On June 3, 2026, 2,619 ordinary shares were withheld at $210.19 per share to cover employment and tax obligations when 5,937 restricted shares vested.

After this withholding, he directly owned 69,964 ordinary shares, including 44,176 restricted shares as of June 3, 2026. These restricted shares are scheduled to lapse in stages between June 4, 2026 and June 4, 2029.

STERIS plc Senior Vice President and CFO Karen L. Burton reported an automatic share disposition tied to tax withholding. On June 3, 2026, 190 ordinary shares were withheld from 651 restricted shares that vested, using the NYSE closing price of $210.19 per share to determine the tax value. This was not an open‑market sale but a payment of taxes in shares.

After this transaction, Burton directly holds 13,274 ordinary shares, of which 9,588 remain restricted as of June 3, 2026. Those restricted shares are scheduled to lapse in stages between June 4, 2026 and June 4, 2029.

STERIS plc senior vice president and general counsel John Adam Zangerle reported routine equity compensation activity and related tax withholding. On June 2, 2026, 247 ordinary shares were withheld to cover taxes on 846 restricted shares that vested, reflecting a tax-withholding disposition rather than an open-market sale.

The same day, he received 4,359 ordinary shares as a grant at no cost and was granted employee stock options for 15,200 ordinary shares with a $230.74 exercise price, vesting in four annual installments from 2027 through 2030 and expiring on June 2, 2036. Following these awards, he directly holds 37,444 ordinary shares, of which 10,867 are restricted as of June 2, 2026.

STERIS plc executive Renato Tamaro, Vice President & Corporate Treasurer, reported routine equity compensation changes. He received 750 ordinary shares as a grant and a new employee stock option for 2,620 ordinary shares at an exercise price of $230.74 per share, expiring on June 2, 2036. To cover tax obligations on previously granted restricted stock, 41 shares were withheld from 141 restricted shares that vested on June 2, 2026, a tax-withholding disposition rather than an open-market sale. Following these transactions, Tamaro holds 6,323 ordinary shares directly, of which 1,843 shares are restricted as of June 2, 2026 and scheduled to vest in tranches between June 3, 2026 and June 4, 2029.

STERIS plc VP Lindsey McGowan reported routine equity compensation changes. On June 2, 2026, 1,128 restricted ordinary shares vested, and 329 shares were withheld at $209.76 per share to cover tax obligations, leaving 5,656 ordinary shares held directly.

McGowan also received a new grant of 1,155 ordinary shares, increasing direct holdings to 5,985 shares, of which 3,117 are restricted as of June 2, 2026. In addition, she was granted 4,036 employee stock options exercisable at $230.74 per share, expiring on June 2, 2036, vesting in four equal annual installments starting in 2027.

Separately, 255 ordinary share equivalents are held for her account under the STERIS Corporation 401(k) Plan as of May 29, 2026. These transactions reflect compensation grants and tax withholding rather than open-market buying or selling.

STERIS plc senior executive Cary L. Majors reported routine equity compensation and related tax withholding. On June 2, 2026, he received a grant of 4,746 ordinary shares, bringing his direct holdings to 17,405 shares. A separate entry shows 67 shares disposed at $209.76 per share solely to satisfy tax obligations on 2,140 restricted shares that vested the same day.

Majors was also granted an employee stock option for 16,548 ordinary shares at an exercise price of $230.74 per share, expiring on June 2, 2036. As of June 2, 2026, 10,047 of his ordinary shares are restricted, scheduled to vest in stages through June 4, 2029. In addition, units representing 67 ordinary share equivalents are held for him under the STERIS Corporation 401(k) Plan.

STERIS plc senior vice president Julia Madsen reported routine equity compensation activity. She received 2,316 ordinary shares as a stock award and a new employee stock option covering 8,080 ordinary shares at an exercise price of $230.74 per share, expiring on June 2, 2036. To cover tax obligations on 352 restricted shares that vested on June 2, 2026, 127 shares were withheld by the company, which is recorded as a tax-withholding disposition rather than an open-market sale. After these transactions, she holds 12,691 ordinary shares directly, of which 5,398 are restricted shares scheduled to vest in tranches between June 2026 and June 2029.

STERIS plc senior executive Kenneth E. Kohler reported routine equity compensation and related tax withholding. He received 2,199 ordinary shares as a grant and 7,668 employee stock options to buy ordinary shares at $230.74 per share, expiring on June 2, 2036.

The filing also shows 66 ordinary shares valued at $209.76 each were withheld to cover taxes on 225 restricted shares that vested on June 2, 2026, rather than sold in the market. After these transactions, he directly holds 11,666 ordinary shares, including 5,115 restricted shares that vest in stages through June 4, 2029.

STERIS plc SVP & Chief HRO Mary Clare Fraser reported equity awards on June 2, 2026. She received a grant of 10,492 employee stock options with an exercise price of 230.74 per share, vesting in four annual tranches from 2027 to 2030 and expiring in 2036. She also acquired 3,009 ordinary shares, while 591 shares were withheld at 209.76 per share to cover tax obligations on 2,028 restricted shares that vested. After these transactions she directly holds 14,627 ordinary shares, of which 7,554 remain restricted with scheduled lapses between 2026 and 2029.

STERIS plc President and CEO Daniel A. Carestio reported equity compensation and related tax withholding transactions. He received 23,736 ordinary shares as a grant and 82,740 employee stock options with an exercise price of $230.74 per share, expiring in 2036.

On the same date, 2,369 restricted shares vested, and 995 of those shares were withheld at $209.76 per share to cover employment and tax obligations, rather than sold in the market. After these transactions, he directly owned 72,583 ordinary shares, of which 50,113 were restricted as of June 2, 2026, subject to a multi-year vesting schedule.

STERIS plc senior vice president and CFO Karen L. Burton reported routine equity compensation changes. She received a grant of 5,325 ordinary shares at a stated price of $0.0000 per share and now directly holds 13,464 ordinary shares. Footnotes state that as of June 2, 2026, 10,239 of these ordinary shares are restricted, with restrictions scheduled to lapse in several tranches between June 3, 2026 and June 4, 2029. The filing also records withholding of 66 shares from 225 restricted shares that vested on June 2, 2026 to cover taxes, valued at the NYSE closing market price of $209.76 per share. In addition, Burton received an employee stock option for 18,564 ordinary shares at an exercise price of $230.74 per share, expiring on June 2, 2036, which becomes exercisable in four equal installments from June 2, 2027 through June 3, 2030.

STERIS plc director Pierre Boulud received a grant of 367 Career Restricted Stock Units. These derivative awards were acquired at a price of 0.0000 per unit and are linked to 367 underlying STERIS ordinary shares.

Each Career Restricted Stock Unit represents the right to receive one ordinary share six months after the end of his Board service. The units are fully vested immediately but will only be settled in shares six months after his service on the Board ceases. Following this grant, he holds 367 Career Restricted Stock Units directly.

STERIS plc director Richard C. Breeden reported option exercises and share sales. On 2026-06-02, he exercised options to acquire 3,781 Ordinary Shares at $71.40 per share and sold 1,481 Ordinary Shares in an open-market transaction at a weighted average price of $209.51 per share.

Following these transactions, Breeden directly owned 38,964 Ordinary Shares. A separate entry shows 27,242 Ordinary Shares held indirectly, with footnotes explaining these are owned through Breeden-affiliated investment entities and that he may be deemed an indirect beneficial owner, while disclaiming beneficial ownership of 1,358 of those shares.

STERIS plc senior vice president and general counsel John Adam Zangerle reported a routine share withholding related to restricted stock vesting. On June 1, 2026, 337 ordinary shares were withheld from 1,157 vested restricted shares to cover tax obligations, based on the NYSE closing price that day.

After this tax-withholding disposition, he directly owned 33,332 ordinary shares, including 7,354 restricted shares as of June 1, 2026. The restrictions on these ordinary shares are scheduled to lapse in tranches through June 5, 2028.

STERIS plc vice president and corporate treasurer Renato Tamaro reported a routine tax-withholding share disposition related to vesting equity awards. On June 1, 2026, 81 ordinary shares were withheld from 241 restricted shares that vested to cover required employment and tax obligations, valued at the NYSE closing market price that day.

After this non-market transaction, Tamaro directly held 5,614 ordinary shares, including 1,234 restricted shares as of June 1, 2026. The filing also outlines the schedule on which these remaining restricted shares are set to lapse over 2026–2028.

STERIS plc executive Lindsey McGowan reported routine share updates related to vesting of restricted stock and associated tax withholding. On June 1, 2026, 660 restricted shares vested, and 198 of those shares were withheld to cover taxes, a non-market "F" code tax-withholding disposition.

After these transactions, McGowan directly holds 4,830 ordinary shares, including 3,090 restricted shares subject to future vesting through January 2, 2029. In addition, 255 ordinary share equivalent units are held on her behalf in the STERIS Corporation 401(k) Plan. No open-market purchases or sales were reported.

STERIS plc senior executive Cary L. Majors reported routine equity compensation activity. On June 1, 2026, 2,697 restricted ordinary shares vested, and 768 of those shares were withheld to cover tax obligations, reflected as a tax-withholding disposition rather than an open-market sale.

After this event, Majors directly held 12,659 ordinary shares, including 7,441 restricted shares as of June 1, 2026, with restrictions scheduled to lapse in tranches through 2028. In addition, units representing 67 ordinary share equivalents were held for Majors under the STERIS Corporation 401(k) Plan.

STERIS plc senior executive Julia Madsen reported a routine tax-withholding share disposition tied to vesting equity compensation. On June 1, 2026, 578 restricted shares vested, and 208 of those shares were withheld to cover required taxes based on the NYSE closing market price that day.

After this transaction, she directly holds 10,502 ordinary shares, including 3,425 restricted shares. The restrictions on these ordinary shares are scheduled to lapse in tranches between June 2026 and June 2028.

STERIS plc senior executive reports routine tax withholding on vested shares. On June 1, 2026, SVP & GM, AST Kenneth E. Kohler had 109 ordinary shares withheld to cover taxes on 373 restricted shares that vested, with the value based on the NYSE closing price on that date.

After this disposition, he directly holds 9,533 ordinary shares, of which 3,141 are still restricted as of June 1, 2026 and scheduled to lapse in stages through June 5, 2028. The filing also corrects previously misreported beneficial ownership amounts.

STERIS plc SVP & Chief HRO Mary Clare Fraser reported a routine tax-withholding share disposition. On June 1, 2026, 2,313 restricted shares vested, and 673 ordinary shares were withheld to cover taxes based on the NYSE closing market price that day. After this withholding, she directly holds 12,209 ordinary shares. As of June 1, 2026, 6,573 of these shares remain restricted, with restrictions scheduled to lapse in several tranches through June 5, 2028.

STERIS plc President and CEO Daniel A. Carestio reported a routine tax-related share disposition. On June 1, 2026, 1,254 ordinary shares were withheld from 4,308 restricted shares that vested, to cover taxes determined under applicable laws at the NYSE closing market price.

After this withholding, Carestio directly holds 49,842 ordinary shares. As of June 1, 2026, 28,746 of these are restricted shares scheduled to lapse over several dates through June 5, 2028, reflecting ongoing equity-based compensation rather than an open-market sale.

STERIS plc reported that Sr. Vice President and CFO Karen L. Burton had 99 ordinary shares withheld on June 1, 2026 to cover tax obligations on vested restricted stock. The Form 4 classifies this as a tax-withholding disposition, not an open-market trade.

The 99 shares were withheld from 340 restricted shares that vested on that date, valued at the NYSE closing market price. After this transaction, Burton directly holds 8,205 ordinary shares, of which 5,139 are restricted with scheduled lapses through October 1, 2028.

STERIS plc director Cynthia L. Feldmann exercised stock options and sold shares in a same‑day transaction. She exercised options for 3,098 ordinary shares through a derivative conversion, then acquired the same number of ordinary shares at a price of $152.32 per share. She subsequently sold 3,098 ordinary shares in an open‑market transaction at a weighted average price of $237.21 per share, leaving 705 ordinary shares held directly. In addition, 8,663 ordinary shares are held indirectly in a revocable trust for which Ms. Feldmann and her husband serve as trustees.

STERIS plc filed a Form 4 reporting an equity award to a company officer. On January 2, 2026, a STERIS officer serving as VP, Chief Comp. & Quality Officer acquired 798 ordinary shares of STERIS plc at a reported price of $0 per share, indicating a share grant rather than an open-market purchase.

After this transaction, the officer beneficially owned 5,028 ordinary shares directly, of which 3,750 shares were restricted as of January 2, 2026. These restricted shares are scheduled to vest in tranches between May 31, 2026 and January 2, 2029. In addition, units representing 248 ordinary share equivalents were held for the officer under the STERIS Corporation 401(k) Plan as of that same date.

STERIS plc (STE) reported insider transactions by its Sr. VP and GM, Life Sciences, on November 21, 2025. The officer exercised employee stock options to buy 2,872 ordinary shares at $114.22 and 2,136 ordinary shares at $147.05, then sold the same numbers of shares in two sales at $262 per share. Following these transactions, the officer beneficially owned 10,710 ordinary shares.

As of November 21, 2025, 4,003 of these 10,710 ordinary shares are restricted, with restrictions scheduled to lapse in several tranches between June 1, 2026 and June 5, 2028. The reported stock options are described as fully vested and now show 0 derivative securities remaining after the exercises.

STERIS plc (STE) officer and V.P. & Corporate Treasurer reported option exercises and share sales. On November 18, 2025, the insider exercised an employee stock option for 3,536 ordinary shares at an exercise price of $182.22 per share, then sold shares in several transactions at market prices around the mid-$250s. Reported sales included 3,324 shares at a weighted average price of $257.43, 212 shares at a weighted average price of $258.03, and 1,500 shares at $257.76 per share.

After these transactions, the reporting person beneficially owned 5,695 ordinary shares, including 1,475 restricted shares as of November 18, 2025. The restricted shares are scheduled to vest in installments between June 1, 2026 and June 5, 2028, and the reported stock option is now fully vested with no remaining balance.

STERIS plc (STE) Form 4: The company’s Senior Vice President, General Counsel and Secretary exercised 15,000 employee stock options at $69.72 per share on 11/11/2025 and sold 15,000 ordinary shares the same day at a weighted average price of $265.14 (range $265.00–$265.95). Following these transactions, the officer directly owned 33,669 shares as of 11/11/2025. Of these, 8,511 are restricted, with scheduled lapses through June 2028.

Director and CEO Daniel A. Carestio reported a small open-market sale of 159 ordinary shares on 10/06/2025 at a price of $241.82 per share, leaving beneficial ownership of 51,096 shares. The filing indicates 33,054 of those shares are restricted with scheduled lapses: 06/01/2026 (4,308), 06/02/2026 (2,369), 06/03/2026 (5,937), 06/04/2026 (4,283), 06/03/2027 (5,937), 06/04/2027 (4,283), and 06/05/2028 (5,937). The form is filed individually and indicates the transaction was reported under a Rule 10b5-1 plan.